Clinical-stage oncology company PharmAust Limited (ASX:PAA), has finalised contractual arrangements for a Phase II canine cancer trial with the University of Melbourne’s U-Vet Werribee Animal Hospital.
PharmAust’s Chief Scientific Officer Dr Richard Mollard said recruitment of canine patients will now commence at U-Vet to formally test monepantel (MPL) in a new palatable and high dose tablet form in pet owners’ dogs with treatment-naïve B cell lymphoma.
The trial at U-Vet, U-Vet one of Australia’s leading veterinary hospitals, will be overseen by Dr Claire Cannon, Head of Small Animal Medicine and Oncology at U-Vet and a specialist veterinary oncologist.
Dr Cannon will also oversee recruitment at other nominated sites within Australia, facilitating accelerated accrual rates, and enabling faster trial endpoint determination. Acceptance for these other sites to participate in the trial is currently being finalised with appropriate agreements.
“PharmAust is very pleased to be working with Dr Cannon and her team at U-Vet and the University of Melbourne. PharmAust is looking forward to sharing the data generated from the trial at U-Vet and other sites when they become available,” Dr Mollard said.
